Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical epinephrine Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
43
States / cities
Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Not yet recruiting Phase 2 Interventional

Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy

NCT07031206
View directory record Official record
Conditions
Anxiety, Pain
Interventions
Paracervical block- Lidocaine without epinephrine, Benzocaine Gel applied to the cervix, Hydroxyzine Hydrochloride
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

NCT03576508
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

NCT04814433
View directory record Official record
Conditions
Opioid Pain Medication
Interventions
Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery

NCT03228914
View directory record Official record
Conditions
Endoscopic Sinus Surgery, Nasal Polyps
Interventions
Oxymetazoline, Epinephrine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Patient Experience Study of Deoxycholic Acid Injection

NCT02007434
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
Drug · Other
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 8, 2026, 10:05 PM EDT
Withdrawn Early Phase 1 Interventional

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

NCT06345833
View directory record Official record
Conditions
Hemophilia, Hemorrhage, Facelift Surgery
Interventions
1%Tranexamic acid with standard local, 3% TXA, 1% TXA with local plus 3% TXA-soaked pledgets
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

NCT02932878
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Steroids for Corneal Ulcers Trial

NCT00324168
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Bacterial
Interventions
Antibiotics, Topical corticosteroid, Placebo
Drug
Lead sponsor
Thomas M. Lietman
Other
Eligibility
16 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
San Francisco, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional Results available

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT01676415
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Prednisone, Topical mometasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

NCT01232543
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Product 0405
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

NCT03126968
View directory record Official record
Conditions
Lung Transplant; Complications, Mechanical, Lung Transplant; Complications, Bleeding, Hemoptysis
Interventions
Topical epinephrine, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 8, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Results available

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

NCT02289989
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oregano extract cream, Hydrocortisone
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 8, 2026, 10:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid (TCS)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

NCT02720627
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Fort Smith, Arkansas • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 8, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

NCT03639857
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
532nm laser, 1064nm laser, Topical corticosteroid
Device · Drug
Lead sponsor
David Weinstein
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 8, 2026, 10:05 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

NCT02153762
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Locoid Lipocream, Hylatopic Plus
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247
View directory record Official record
Conditions
Keloid, Hypertrophic Scar, Cicatrix, Hypertrophic
Interventions
0.5% hydrocortisone, silicone, vitamin E lotion, Onion extract gel, Cetearyl alcohol lotion
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Boise, Idaho • Carmel, Indiana • Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 8, 2026, 10:05 PM EDT